You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Reimbursement news and insurance coverage updates.
From 2009 to 2012, the laboratory allegedly billed Medicare for testing on hospital inpatients that should have been billed to the hospitals.
The payor says that the registry will provide needed transparency around test orders, but labs say it is an unnecessary burden, especially amidst a pandemic.
The contractors will provide limited coverage for ctDNA tests if the patient has a personal history of stage II to stage III colorectal cancer.
Under a proposed rule, devices given FDA's breakthrough designation would, upon receiving FDA market authorization, immediately be covered by Medicare.
Saying pooled testing for coronavirus was not for diagnostic purposes, Cigna had said it wouldn't reimburse for the method, but it plans to change its policy.